









**VOLUME 131** 

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 2–18 March 2022

LYON, FRANCE - 2023

IARC MONOGRAPHS
ON THE IDENTIFICATION
OF CARCINOGENIC HAZARDS
TO HUMANS

## **IARC MONOGRAPHS**

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme on the evaluation of the carcinogenic hazard of chemicals to humans, involving the production of critically evaluated monographs on individual chemicals. The programme was subsequently expanded to include evaluations of carcinogenic hazards associated with exposures to complex mixtures, lifestyle factors and biological and physical agents, as well as those in specific occupations. The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for agents to which humans are known to be exposed and on specific exposure situations; to evaluate these data in terms of cancer hazard to humans with the help of international working groups of experts in carcinogenesis and related fields; and to identify gaps in evidence. The lists of IARC evaluations are regularly updated and are available on the internet at <a href="https://monographs.iarc.who.int/">https://monographs.iarc.who.int/</a>.

This programme has been supported since 1982 by Cooperative Agreement U01 CA33193 with the United States National Cancer Institute, Department of Health and Human Services. Additional support has been provided since 1986 by the European Commission Directorate-General for Employment, Social Affairs, and Inclusion, initially by the Unit of Health, Safety and Hygiene at Work, and since 2014 by the European Union Programme for Employment and Social Innovation "EaSI" (for further information please consult: <a href="https://ec.europa.eu/social/easi">https://ec.europa.eu/social/easi</a>). Support has also been provided since 1992 by the United States National Institute of Environmental Health Sciences, Department of Health and Human Services. The contents of this volume are solely the responsibility of the Working Group and do not necessarily represent the official views of the United States National Cancer Institute, the United States National Institute of Environmental Health Sciences, the United States Department of Health and Human Services, or the European Commission.



Co-funded by the European Union

Published by the International Agency for Research on Cancer, 25 avenue Tony Garnier, CS 90627, 69366 Lyon CEDEX 07, France ©International Agency for Research on Cancer, 2023 Online publication, May 2023

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

*IARC Monographs* (and Corrigenda) are published online at <a href="https://publications.iarc.fr">https://publications.iarc.fr</a>. To report an error, please contact: <a href="mailto:imo@iarc.who.int">imo@iarc.who.int</a>.

Distributed by WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; website: <a href="https://apps.who.int/bookorders">https://apps.who.int/bookorders</a>; email: <a href="mailto-bookorders@who.int">bookorders@who.int</a>).

Permissions and rights: Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO licence (CC BY-NC-ND 3.0 IGO; <a href="https://creativecommons.org/licenses/by-nc-nd/3.0/igo/">https://creativecommons.org/licenses/by-nc-nd/3.0/igo/</a>).

Under the terms of this licence, you may copy and redistribute the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products, or services. The use of the WHO logo is not permitted. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

To submit requests for adaptations or commercial use and queries on rights and licensing, see the IARC Publications website (https://publications.iarc.fr/Rights-And-Permissions).

Third-party materials: If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers: The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO or contributing agencies be liable for damages arising from its use.

The IARC Monographs Working Group alone is responsible for the views expressed in this publication.



About the cover: Workers involved in smelting processes are potentially exposed to cobalt metal and cobalt compounds, and to antimony.

Source: © AdobeStock.com/Panksvatouny

How to cite: IARC (2023). Cobalt, antimony compounds, and weapons-grade tungsten alloy. *IARC Monogr Identif Carcinog Hazards Hum.* 131:1–594.

## IARC Library Cataloguing-in-Publication Data

Names: IARC Working Group on the Identification of Carcinogenic Hazards to Humans.

Title: Cobalt, antimony compounds, and weapons-grade tungsten alloy.

Description: Lyon: International Agency for Research on Cancer, 2023. | Series: IARC monographs on the identification of carcinogenic hazards to humans, ISSN 1017-1606; v. 131. | "This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 2–18 March 2022." | Includes bibliographical references.

Identifiers: ISBN 9789283201717 (pbk.) | ISBN 9789283201984 (ebook)

Subjects: MESH: Carcinogens--toxicity. | Neoplasms--chemically induced. | Cobalt--adverse effects. | Antimony --adverse effects. | Tungsten--adverse effects.

Classification: NLM W1

## ARC MONDERAPHS

This volume of the *IARC Monographs* provides evaluations of the carcinogenicity of nine agents: cobalt metal (without tungsten carbide or other metal alloys), soluble cobalt(II) salts, cobalt(II) oxide, cobalt(II) oxide, cobalt(II) sulfide, other cobalt(II) compounds, trivalent antimony, pentavalent antimony, and weapons-grade tungsten (with nickel and cobalt) alloy.

Cobalt is used in the manufacture of cutting and grinding tools, in pigments, paints, coloured glass, medical implants, and electroplating, and in lithium-ion battery production. Occupational exposure is expected to occur during cobalt refining and production of cobalt compounds and dental materials, use of diamond-cobalt tools, plate painting with cobalt pigments, manufacture of nickel-hydrogen batteries, hard-metal production, and electronic-waste recycling. The general population is exposed via food, air, tobacco smoke, and medical implants.

Antimony is used in flame retardants, lead-acid batteries and alloys, plastics, brake pads, clutch discs, glass, ceramics, and as a primer in explosives. Some pentavalent antimony compounds are used to treat leishmaniasis. Workers can be exposed during smelting, manufacture of antimony compounds, glass, textiles, and batteries, and electrical-waste processing. Non-occupational exposures occur via water, air, soil, consumer products, and tobacco.

Weapons-grade tungsten (with nickel and cobalt) alloy is used in armour-penetrating munitions. Occupational exposure can occur during munitions production, and military personnel and civilians can be exposed to metal aerosols generated during firing or impact, or via injuries with retained embedded fragments.

An *IARC Monographs* Working Group reviewed evidence from cancer studies in humans (available mainly for cobalt and antimony), cancer bioassays in experimental animals, and mechanistic studies to assess the carcinogenic hazard to humans of exposure to these agents and concluded that:

- Cobalt metal (without tungsten carbide or other metal alloys), soluble cobalt(II) salts, and trivalent antimony are probably carcinogenic to humans (Group 2A);
- Cobalt(II) oxide and weapons-grade tungsten (with nickel and cobalt) alloy are possibly carcinogenic to humans (Group 2B);
- Cobalt(II,III) oxide, cobalt(II) sulfide, other cobalt(II) compounds, and pentavalent
  antimony were each evaluated as not classifiable as to its carcinogenicity to
  humans (Group 3).

